Coli-induced Infection Research Articles

Identification of Escherichia coli isolated from flies (Insecta: Diptera) that inhabit the environment of dairy farms harboring extraintestinal virulence markers.

We investigate extraintestinal pathogenic genes (ExPEC) related to virulence of Escherichia coli in flies from the dairy environment. We collected 217 flies from nine dairy farms, which were submitted to microbiological culture. Fifty-one E. coli were identified using mass spectrometry. Eleven dipteran families were identified, with a predominance of Muscidae, and a minor frequency of Tachinidae, Drosophilidae, Sphaeroceridae, Ulidiidae, Syrphidae, Chloropidae, Calliphoridae, Sarcophagidae, and Piophilidae. A panel of 16 virulence-encoding genes related to ExPEC infections were investigated, which revealed predominance of serum resistance (traT, 31/51=60.8%; ompT, 29/51=56.9%), iron uptake (irp2, 17/51=33.3%, iucD 11/51=21.6%), and adhesins (papC, 6/51=11.8%; papA, 5/51=9.8%). Our findings reveal Dipterans from milking environment carrying ExPEC virulence-encoding genes also identified in clinical bovine E. coli-induced infections.

Treatment with a Urinary Bladder Matrix Alters the Innate Host Response to Pneumonia Induced by Escherichia coli.

Escherichiacoli has become the prominent cause of nosocomial pneumonia in recent years. In the meantime, some strains of E. coli have developed resistance to commonly used antibacterial drugs. The urinary bladder matrix (UBM) is a biologically derived scaffold material that has been used to promote site-appropriate tissue remodeling in a variety of body systems, partially through the modulation of the innate immune response. In this study, we seek to determine UBM efficacy in preventing bacterial pneumonia in mouse lungs using the Gram-negative bacterial strain E. coli. Our results show that the UBM prevented bacterial biofilm formation in both abiotic and biotic conditions through experimentation on polystyrene plates and culture on the apical surface of differentiated airway epithelial cells. Intratracheal treatment with UBM led to host protection from E. coli-induced respiratory infection in a murine pneumonia model. Transcriptomic analysis revealed the involvement of the enhanced host immune response in UBM-treated mice. Additionally, UBM-treated macrophages had an increased iNOS expression and enhanced phagocytosis activity. Therefore, the protection against E. coli-induced infection and the antibacterial function observed by UBM is potentially through both the anti-biofilm activity and enhanced host immunity following UBM treatment. Taken together, our results support further investigation of UBM as an alternative treatment to attenuate bacterial-induced respiratory infection.

Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli.

Escherichia coli and Staphylococcus aureus are important agents of urinary tract infections that can often evolve to severe infections. The rise of antibiotic-resistant strains has driven the search for novel therapies to replace the use or act as adjuvants of antibiotics. In this context, plant-derived compounds have been widely investigated. Cuminaldehyde is suggested as the major antimicrobial compound of the cumin seed essential oil. However, this effect is not fully understood. Herein, we investigated the in silico and in vitro activities of cuminaldehyde, as well as its ability to potentiate ciprofloxacin effects against S. aureus and E. coli. In silico analyses were performed by using different computational tools. The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde. For analysis of the possible toxic effects and the theoretical pharmacokinetic parameters of the compound, the Osiris, SwissADME and PROTOX programmes were used. Estimations of cuminaldehyde gastrointestinal absorption, blood brain barrier permeability and skin permeation by using SwissADME; and drug likeness and score by using Osiris, were also evaluated The in vitro antimicrobial effects of cuminaldehyde were determined by using microdilution, biofilm formation and time-kill assays. In silico analysis indicated that cuminaldehyde may act as an antimicrobial and as a membrane permeability enhancer. It was suggested to be highly absorbable by the gastrointestinal tract and likely to cross the blood brain barrier. Also, irritative and harmful effects were predicted for cuminaldehyde if swallowed at its LD50. Good oral bioavailability and drug score were also found for this compound. Cuminaldehyde presented antimicrobial and anti-biofilm effects against S. aureus and E. coli.. When co-incubated with ciprofloxacin, it enhanced the antibiotic antimicrobial and anti-biofilm actions. We suggest that cuminaldehyde may be useful as an adjuvant therapy to ciprofloxacin in S. aureus and E. coli-induced infections.

Contribution of the serine protease HtrA in Escherichia coli to infection in foxes

Escherichia coli can cause severe, acute hemorrhagic pneumonia and systemic infection in farmed foxes, raccoon dogs and minks, leading to considerable economic losses to the farmers. It is well established that the htrA-encoded serine protease HtrA is critical for bacterial growth and survival under stress, and HtrA has been determined to be a potential vaccine target. However, the roles of HtrA in E. coli pathogenesis remain unknown. In this study, we generated an htrA-deletion mutant of the E. coli protype strain HBCLE-12 that causes pneumonia in silver foxes and then evaluated the changes in bacterial physiological characteristics in the absence of HtrA. The data show that knockout of the htrA gene did not affect growth and biochemical characteristics but led to impaired virulence of the strain. Increased susceptibility to environmental stresses, impaired survival in serum, and reduced biofilm formation may contribute to the virulence attenuation of the mutant. Furthermore, the HtrA-deficient mutant was subjected to RNA-seq analysis, and 16 differentially expressed genes were determined. This study provided insight that HtrA plays a definitive role in E. coli-induced infection.

Cytotoxic Escherichia coli strains encoding colibactin isolated from immunocompromised mice with urosepsis and meningitis.

Immune-compromised mouse models allow for testing the preclinical efficacy of human cell transplantations and gene therapy strategies before moving forward to clinical trials. However, CRISPR/Cas9 gene editing of the Wsh/Wsh mouse strain to create an immune-compromised model lacking function of Rag2 and Il2rγ led to unexpected morbidity and mortality. This warranted an investigation to ascertain the cause and predisposing factors associated with the outbreak. Postmortem examination was performed on 15 moribund mice. The main lesions observed in these mice consisted of ascending urogenital tract infections, suppurative otitis media, pneumonia, myocarditis, and meningoencephalomyelitis. As Escherichia coli strains harboring polyketide synthase (pks) genomic island were recently isolated from laboratory mice, the tissue sections from the urogenital tract, heart, and middle ear were subjected to E. coli specific PNA-FISH assay that revealed discrete colonies of E. coli associated with the lesions. Microbiological examination and 16S rRNA sequencing confirmed E. coli-induced infection and septicemia in the affected mice. Further characterization by clb gene analysis and colibactin toxicity assays of the pks+ E. coli revealed colibactin-associated cytotoxicity. Rederivation of the transgenic mice using embryo transfer produced mice with an intestinal flora devoid of pks+ E. coli. Importantly, these barrier-maintained rederived mice have produced multiple litters without adverse health effects. This report is the first to describe acute morbidity and mortality associated with pks+ E. coli urosepsis and meningitis in immunocompromised mice, and highlights the importance of monitoring and exclusion of colibactin-producing pks+ E. coli.

Change of Plasma Nitric Oxide during Acute Rejection or Infection after Lung Allotransplantation

Objective This study was aimed to investigate whether there is any change in palsma nitric oxide during acute rejection of infection after lung allotransplantation. Methods After lung allotransplantation, dogs were immunosuppressed with standardized triple therapy and divided into 3 groups : in group 1(control: n=4), immunosuppression was maintained; in group 2(n=7), triple therapy discontinued to induce acute rejection at the postoperative day 5; in group 3(n=6), infection was inudced by bronchoscopic inoculation of E. coli at the postoperative day 5. Plasma nitric oxide was measured by chemiluminescene method prior to surgery(day 0), and at postoperative day 5 and 9. In each group, plasma nitric oxide level at day 9 was compared to that at day 0. Plasma nitric oxide levels at day 9 were compared in three groups. Results During acute rejection period, plasma nitric oxide concentration was found to be elevated significantly at postoperative day 9, compared to day 0(11.52±2.58 vs 6.01±0.88uM/L ; p<0.05). However, plasma nitric oxide concentration wasn't altered by the E. coli-induced infection(14.53±5.19 vs 6.12±0.98uM/L ; p>0.05). Plasma nitric oxide of day 9 weren't different in three groups(p>0.05). Conclusion Plasma nitric oxide may be a good marker for acute rejection after allotrans-plantation, but not for infection.